ARS Pharmaceuticals Ownership | Who Owns ARS Pharmaceuticals?

Overview Forecast RevenueFinancials Chart Transcripts

ARS Pharmaceuticals Ownership Summary

ARS Pharmaceuticals is owned by 84.83% institutional investors, 16.83% insiders. Ra capital management is the largest institutional shareholder, holding 11.04% of SPRY shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 1.90% of its assets in ARS Pharmaceuticals shares.

SPRY Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	ARS Pharmaceuticals	84.83%	16.83%	-1.66%
Sector	Healthcare Stocks	42.54%	10.83%	46.63%
Industry	Biotech Stocks	45.22%	10.75%	44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ra capital management	10.86M	11.04%	$109.15M
Orbimed advisors	8.29M	8.43%	$83.30M
Deerfield management company, l.p. (series c)	7.50M	7.63%	$75.41M
Blackrock funding, inc. /de	4.83M	4.91%	$48.55M
Rubric capital management lp	4.50M	4.57%	$45.23M
Sr one capital management, lp	4.01M	4.08%	$40.33M
Vanguard group	3.50M	3.56%	$35.18M
Abrdn	3.10M	3.15%	$31.13M
State street	2.90M	2.94%	$29.10M
Alliancebernstein	2.64M	2.69%	$26.55M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sr one capital management, lp	4.01M	5.83%	$40.33M
Bioimpact capital	1.30M	2.14%	$13.10M
Orbimed advisors	8.29M	1.96%	$83.30M
Nextech invest	936.73K	1.60%	$9.88M
Ra capital management	10.86M	1.34%	$109.15M
Casdin capital	1.60M	1.34%	$16.08M
Deerfield management company, l.p. (series c)	7.50M	1.15%	$75.41M
Nextech invest	660.70K	1.01%	$6.64M
Levin capital strategies	764.29K	0.69%	$7.68M
Eversept partners, lp	976.51K	0.68%	$9.81M

Top Buyers

Holder	Shares	% Assets	Change
Rubric capital management lp	4.50M	0.51%	3.21M
Casdin capital	1.60M	1.34%	1.60M
Abrdn	3.10M	0.05%	1.59M
Bamco inc /ny/	1.27M	0.03%	1.23M
Qube research	1.03M	0.01%	1.03M

Top Sellers

Holder	Shares	% Assets	Change
Deerfield management company, l.p. (series c)	7.50M	1.15%	-2.22M
Adage capital partners gp	-	-	-1.73M
Wellington management group llp	-	-	-1.43M
Octagon capital advisors lp	-	-	-1.35M
Alliancebernstein	2.64M	0.01%	-1.18M

New Positions

Holder	Shares	% Assets	Change	Value
Casdin capital	1.60M	1.34%	1.60M	$16.08M
Qube research	1.03M	0.01%	1.03M	$10.40M
Eversept partners, lp	976.51K	0.68%	976.51K	$9.81M
Centerbook partners lp	512.37K	0.25%	512.37K	$5.15M
Empire life investments	355.69K	0.21%	355.69K	$3.57M

Sold Out

Holder	Change
National bank of canada /fi/	-1.00
Eversource wealth advisors	-6.00
True wealth design	-21.00
Stephens consulting	-30.00
Capital performance advisors llp	-33.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	196	1.03%	83,443,647	-1.27%	84	1.15%	111	-1.77%	46	-
Jun 30, 2025	192	1.59%	84,508,656	10.87%	85	1.42%	111	12.12%	46	-16.36%
Mar 31, 2025	188	8.05%	76,205,334	6.92%	77	1.44%	99	2.06%	54	20.00%
Dec 31, 2024	164	1.23%	68,247,890	6.54%	70	1.61%	88	-14.56%	44	69.23%
Sep 30, 2024	162	35.00%	64,056,669	2.41%	66	1.58%	103	51.47%	26	8.33%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	1.86M	1.90%	-
Vanguard Total Stock Mkt Idx Inv	1.75M	1.78%	-38.90K
iShares Russell 2000 ETF	1.33M	1.34%	-
AB Small Cap Growth A	1.05M	1.06%	-56.95K
Franklin Biotechnology Discv A(acc)USD	1.05M	1.06%	-
SPDR® S&P Biotech ETF	984.97K	1.00%	2.20K
abrdn Healthcare Investors	972.99K	0.98%	389.00K
Fidelity Select Biotechnology	902.76K	0.91%	-41.40K
MEDICAL BioHealth EUR Acc	814.27K	0.82%	-
AB Discovery Growth A	741.25K	0.75%	-39.89K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 13, 2025	Dorsey Brian	Chief Operating Officer	Sell	$190.05K
Nov 12, 2025	Chakma Justin	Chief Business Officer	Sell	$267.36K
Nov 12, 2025	Chakma Justin	Chief Business Officer	Sell	$1.21M
Aug 21, 2025	Lowenthal Richard E	PRESIDENT AND CEO	Sell	$724.35K
Aug 21, 2025	Scott Kathleen D.	Chief Financial Officer	Sell	$187.50K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	3
2025 Q3	-	5
2025 Q2	-	6
2025 Q1	-	5
2024 Q4	-	58

SPRY Ownership FAQ

Who Owns ARS Pharmaceuticals?

ARS Pharmaceuticals shareholders are primarily institutional investors at 84.83%, followed by 16.83% insiders and -1.66% retail investors. The average institutional ownership in ARS Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which ARS Pharmaceuticals exceeds.

Who owns the most shares of ARS Pharmaceuticals?

ARS Pharmaceuticals’s largest shareholders are Ra capital management (10.86M shares, 11.04%), Orbimed advisors (8.29M shares, 8.43%), and Deerfield management company, l.p. (series c) (7.5M shares, 7.63%). Together, they hold 27.10% of ARS Pharmaceuticals’s total shares outstanding.

Does Blackrock own ARS Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of ARS Pharmaceuticals.

Who is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.83% of its assets in 4.01M ARS Pharmaceuticals shares, valued at 40.33M$.

Who is the top mutual fund holder of ARS Pharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of ARS Pharmaceuticals shares, with 1.90% of its total shares outstanding invested in 1.86M ARS Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools